F2G Alternatives & Competitors
12 companies similar to F2G — The rare fungal disease company
Companies similar to F2G
Solid Biosciences
#TogetherWeAreSolid
Boston, United States
ContraFect Corp
...focused on discovering & developing differentiated biologic therapies for life-threaten...
Yonkers, United States
Stockholm, Sweden
Eiger BioPharmaceuticals
Developing innovative therapies to treat and cure rare metabolic diseases
Rival Readout
Competing with F2G? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Alkeus Pharmaceuticals, Inc.
Transformation in Sight
Ansun Biopharma, Inc.
Discovering solutions for the world
San Diego, United States
Zevra Therapeutics
A Rare Approach to Therapeutics
Celebration, United State...
Spero Therapeutics
Clinical-stage biotech company focused on rare diseases and diseases with high unmet need
Cambridge, United States
Barinthus Biotherapeutics
Barinthus is a clinical-stage biopharmaceutical company developing novel T-cell immunother...
Oxford, United Kingdom
bluebird bio
Pursuing curative gene therapies to give patients and their families more bluebird days.
Somerville, United States
BlueRock Therapeutics
Striving to transform the treatment of disease by harnessing the power of cell therapy
Cambridge, United States
About F2G
F2G, known as "The rare fungal disease company," is a pioneering clinical-stage biopharmaceutical firm headquartered in the United Kingdom. Founded in 1998, the company is at the forefront of developing therapies for life-threatening invasive fungal infections. Central to F2G's innovation is the creation of a novel cla...
Development of Antifungal Therapies, Research and Development in Fungal Infections, Early Access to Investigational Therapies
Patients with Rare Fungal Infections, Healthcare Providers, Medical Researchers
Biopharmaceutical, Clinical-stage, Fungal Disease, Orotomides, Antifungal Agents, Invasive Fungal Infections, Dihydroorotate Dehydrogenase, Pyrimidine Biosynthesis, Olorofim, Fungicidal Activity, Rare Mould Infections, Phase 3 Trial, Orphan Drug Status, Breakthrough Therapy Designation, Proprietary Genomics Technology
B2B, B2D
Product Sales, Licensing, Service Fee
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around F2G: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at F2G on 11 Mar 2026. The 12 companies listed here were last checked between 11 Sep 2024 and 3 Jul 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
